Ultragenyx Pharmaceutical Inc. Common Stock (RARE)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Ultragenyx through a Graham-and-Buffett lens, I see a commercial-stage rare-disease biotech with real revenue but no earnings. Revenue rose from $434.0M in fiscal 2023 to $560.0M in fiscal 2024 and $673.0M in fiscal 2025, so the top line is moving in the right direction. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $214.0M and net income was -$92.0M, or diluted EPS -$0.90. That is an improvement from fiscal Q2 2025, when revenue was $167.0M and net income was -$115.0M, but the company is still unprofitable. For the full fiscal year 2025, net income was -$575.0M on $673.0M of revenue, and trailing free cash flow was -$494.0M. At the $14.92 close on 2026-10-13, FairStock calculations show a negative P/E of -2.56, ROE of -608.47%, ROCE of -24.22%, and FCF yield of -33.6%. The FairStock score is 23/100, with a Piotroski F-Score of 3/9 and an Altman Z-Score of -4.54, which point to financial stress. There may be a specialized moat in rare disease, but it is not visible in the numbers. The stock is not cheap on earnings because there are none; it is a hope-and-growth story, not a Graham bargain. I would want evidence of shrinking losses, positive cash flow, and less reliance on external financing before calling it a durable business.

In plain English: Ultragenyx is a biotech company that develops and sells medicines for rare genetic diseases. It is growing sales, but it still loses money and uses more cash than it brings in. At $14.92 a share, the price is near its 52-week low, but the numbers do not show a proven, profitable business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer